MX2024012802A - Belumosudil para tratar la disfuncion de aloinjerto pulmonar cronica - Google Patents

Belumosudil para tratar la disfuncion de aloinjerto pulmonar cronica

Info

Publication number
MX2024012802A
MX2024012802A MX2024012802A MX2024012802A MX2024012802A MX 2024012802 A MX2024012802 A MX 2024012802A MX 2024012802 A MX2024012802 A MX 2024012802A MX 2024012802 A MX2024012802 A MX 2024012802A MX 2024012802 A MX2024012802 A MX 2024012802A
Authority
MX
Mexico
Prior art keywords
belumosudil
chronic lung
allograft dysfunction
treating chronic
lung allograft
Prior art date
Application number
MX2024012802A
Other languages
English (en)
Spanish (es)
Inventor
Corey S Cutler
Zachariah Michael Defilipp
Haesook T Kim
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of MX2024012802A publication Critical patent/MX2024012802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024012802A 2022-04-19 2024-10-16 Belumosudil para tratar la disfuncion de aloinjerto pulmonar cronica MX2024012802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US202263389444P 2022-07-15 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (1)

Publication Number Publication Date
MX2024012802A true MX2024012802A (es) 2024-11-08

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012802A MX2024012802A (es) 2022-04-19 2024-10-16 Belumosudil para tratar la disfuncion de aloinjerto pulmonar cronica

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
CN119031914A (zh) 2024-11-26
TW202404602A (zh) 2024-02-01
AU2023256541A1 (en) 2024-12-05
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
MX2021010545A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
MX2021004579A (es) Métodos para trasplante de células madre hematopoyéticas alogénicas.
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
MX2024012802A (es) Belumosudil para tratar la disfuncion de aloinjerto pulmonar cronica
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
AR067543A1 (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
WO2007092196A3 (en) Compositions and methods for treating myeloid proliferative disorders
MX370404B (es) Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
MX2021011958A (es) Terapias genicas para trastornos lisosomales.
BR102012012673A8 (pt) célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
MX2020005388A (es) Uso de composiciones farmacéuticas que comprenden dapagliflozina e inhibidores de sglt2.
MX2025006990A (es) Compuesto quimerico protac, metodo de preparacion del mismo y uso del mismo
BR112022004861A2 (pt) Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
WO2020219778A3 (en) Anti-cd117 antibody-drug conjugates and uses thereof
MX2020010738A (es) Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).
EA201691980A1 (ru) Способы уменьшения побочных эффектов, связанных с химиотерапией
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
MX2024010480A (es) Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica.
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
MX2025002312A (es) Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina
MX2024010925A (es) Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple
Esquirol et al. Combining three different pretransplantation scores improves predictive value in patients after haploidentical stem cell transplantation with thiotepa, busulfan, and fludarabine conditioning and post-transplantation cyclophosphamide